Erratum: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial (Lancet (2015) 385 (1853-1862))

C. H. Moskowitz, A. Nademanee, T. Masszi

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Erratum: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkins lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial (Lancet (2015) 385 (1853-1862))'. Together they form a unique fingerprint.